Multiple Sclerosis and Special Populations (Certified by ParadigMS)
About this e-learning
Welcome to our e-learning on “Multiple Sclerosis and Special Populations”.
This e-learning module explores two critical topics in multiple sclerosis (MS) management. The first presentation, by Prof. Celia Oreja-Guevara, focuses on managing MS in women of childbearing age, particularly during pregnancy and postpartum. The second, by Prof. Patrick Vermersch, examines the unique challenges of managing MS in individuals aged 55 and above, highlighting age-related considerations and treatment strategies. Together, these presentations provide valuable insights for optimizing MS care across diverse patient populations.
Certificate
Participants will gain a ParadigMS Certificate upon completion.
The learning material has been submitted for EACCME Accreditation.
Learning objectives
Prof. Celia Oreja-Guevara – Managing MS During Pregnancy
This presentation focuses on the impact of MS on pregnancy, predictors of postpartum relapses, and safe use of disease-modifying therapies (DMTs) before, during, and after pregnancy. It also provides guidance on breastfeeding, labour, and delivery considerations for women with MS.
Learning Objectives:
- Understand the interplay between pregnancy and MS disease activity.
- Evaluate the safety profiles of disease-modifying therapies (DMTs) during pregnancy and postpartum.
- Identify predictors of postpartum relapse and strategies to minimize risks.
- Discuss the potential impact of breastfeeding on MS progression and treatment choices.
- Assess best practices for pre-pregnancy planning and monitoring in women with MS.
- Recognize the importance of personalized treatment approaches to optimize outcomes for both mother and child.
Prof. Patrick Vermersch – Managing MS in Individuals Aged 55 and Above
This presentation addresses the challenges of managing MS in older adults, including age-related changes in immune function, progression from relapsing to progressive forms of MS, and the impact of comorbidities. It emphasizes strategies for balancing risks and benefits in treatment and the concept of exit strategies for discontinuing therapy.
Learning Objectives:
- Understand that older MS patients often transition from relapsing-remitting to progressive phases, with compartmentalized inflammation playing a central role.
- Understand how Immunosenescence and comorbidities complicate treatment, increasing the risk of infections and reducing the effectiveness of some therapies.
- Discuss exit strategies for DMT discontinuation with their patients, particularly in non-active MS patients over 55.
- Recognize the importance of a patient-centred approach, considering age, comorbidities, and long-term care goals, in optimizing outcomes
